ABERA — Abera Bioscience AB Income Statement
0.000.00%
Last trade - 00:00
- SEK66.53m
- SEK63.21m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | SAS | SAS | SAS | SAS | — |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | — |
Selling / General / Administrative Expenses | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2.47 | 3.64 | 9.16 | 19.4 | 16.8 |
Operating Profit | -2.47 | -3.64 | -9.16 | -19.4 | -16.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.47 | -3.64 | -9.17 | -19.4 | -16.7 |
Net Income After Taxes | -2.47 | -3.64 | -9.17 | -19.4 | -16.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.47 | -3.64 | -9.17 | -19.4 | -16.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.47 | -3.64 | -9.17 | -19.4 | -16.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.236 | -0.348 | -0.792 | -1.5 | -1.16 |
Dividends per Share |